Business Wire

Investor Tej Kohli Expands ‘Venture Philanthropy’ Into 3d-printed Bionic Arms

29.11.2019 10:00:00 EET | Business Wire | Press release

Share

Investor Tej Kohli is to fund the purchase of ten bionic arms for children with limb differences in the UK. The Tej Kohli Foundation hopes that its commitment to fund arms for ten children over the next 5 months as part of its ‘Future Bionics’ program will highlight how assistive technology can substantially improve the lives and confidence of young people living with disabilities. The Tej Kohli Foundation hopes to inspire and influence other healthcare institutions to follow this lead and discover the advanced 3D-printed technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005558/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tej Kohli Foundation co-Founder Wendy Kohli, Tilly Lockey wearing Open Bionics arms, Tej Kohli Foundation co-Founder Tej Kohli, future Hero Arm recipient Jacob Pickering, future Hero Arm recipient Harris Gribble (Photo: Business Wire)

In England the National Health Service (‘NHS’) currently provides a single-grip myoelectric-controlled (‘myo’) prosthesis at a cost of approximately £8,000. However, the Open Bionics Hero Arm can be controlled with the electrical signals generated by a user’s muscles and has superior multi-grip functionality that enables users to perform many more everyday activities.

The Open Bionics Hero Arm costs £10,000 through a private prosthetics clinic in the UK, whereas other advanced multi-grip bionic hands cost £30,000 - £60,000. The Tej Kohli Foundation will spend an initial £100,000 to launch its ‘Future Bionics’ programme, which will enable ten British children to access not just a superior technology, but a better life.

The first Hero Arm recipient is 10-year-old Jacob Pickering from Blackburn, who will receive his new Hero Arm just in time for Christmas. Jacob was born without his right arm as a result of amniotic band syndrome. All Jacob has spoken about for the past month is the Hero Arm, and his father David is “completely overwhelmed” that Jacob has been selected for a donation and claims that it will “change Jacob’s life”. The second Hero Arm recipient is 14-year-old Harris Gribble from Exeter, who is a keen Rugby and Cricket player.

The lightweight Hero Arm is currently the only multi-grip myo prosthetic arm that is available for paediatric use. The enhanced ability of the user to be able to personalise their 3D-printed Open Bionics Hero Arm is also a huge boost to mental well-being and to perceived social acceptance. This is particularly important for younger people.

Investor Tej Kohli first discovered Bristol-based Open Bionics when he invested into ‘Rewired’, a robotics-focused venture studio ‘with a humanitarian bent’ that was a very-early backer of Open Bionics in 2017.

Tej Kohli, Co-Founder of the Tej Kohli Foundation said:

“We started the Tej Kohli Foundation in 2005 with a project to provide daily meals for 1,000 children in Costa Rica. Since then the Tej Kohli Foundation has supported projects all over the world and helped tens of thousands of people, especially those living with disability. This gift of ten bionic arms is the first project that we have ever initiated in the UK. I see it as just the beginning, and my hope is that this gift will help to highlight the positive difference that technology can make to the confidence and prospects of a younger person. We’re doing this as an example, but we hope that others will follow our lead. These technologies are now so accessible and affordable that healthcare organisations such as the NHS should do more to embrace and improve access to them for disabled young people.”

Samantha Payne, Co-Founder and COO of Open Bionics said:

“We’re really grateful to the Tej Kohli Foundation for pledging to fund advanced bionic arms for ten children in the UK. These children are amongst dozens of people with upper limb differences in the UK fundraising right now for a Hero Arm. We've worked really hard to achieve a price point for the device that is acceptable for existing NHS budgets for prosthetic provision, and we very much hope the NHS sees how helpful these devices are and will begin offering them to the people who need them.”

Children and adults with below-elbow limb differences can register their interest at www.openbionics.com.

Images and profiles of the recipients of the Hero Arms can be downloaded here: https://www.dropbox.com/sh/wakjc66nz1ljjpb/AADwtFqgu7j-xhEtTRzYuBdsa?dl=0

About Open Bionics

Open Bionics was founded in 2014 by Joel Gibbard and Samantha Payne with the goal of developing affordable, assistive devices that enhance the human body. In other words, Open Bionics turns disabilities into superpowers. The Bristol-based bionics company is known globally for using 3D printing and 3D scanning, along with some clever software and design, to make advanced, affordable and accessible bionic limbs. In May 2018, the company released the Hero Arm, the world’s first medically approved 3D-printed bionic arm, and the very first multi-grip bionic arm for children as young as eight years old. The Hero Arm is available now through private prosthetic clinics all around the world. Open Bionics have a development contract with NHS England, with the aim of offering the Hero Arm on the NHS in the UK. They also have royalty-free licensing agreements with Disney, Marvel, Lucasfilm, Eidos Montreal and Twentieth Century Fox, making science fiction a reality.

http://www.openbionics.com

About the Tej Kohli Foundation

Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness, which disproportionately impacts young people in poorer countries. Since 2015 the Foundation has funded free corneal transplants in poor communities in India; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness.

Through its ‘Impact Initiatives’ the Tej Kohli Foundation also makes direct interventions into the lives of young people whose confidence and prospects can be substantially improved. Previous ‘Impact Initiatives’ have included financial support for disabled children in Costa Rice, feeding schoolchildren at after-school clubs in poor communities, and also producing a short film to highlight the plight of young people in India living with a rare genetic disease.

http://www.tejkohlifoundation.com

About Tej Kohli

Tej Kohli is a London-based investor and philanthropist who first rose to success selling technology solutions and payments software during the dot com boom. His current focus is as a real estate investor within the world’s newly emerging technology hubs, and as a backer of high-impact AI, robotics and genomics ventures that have the potential to transform lives and change the world. He is also a major esports investor.

Tej Kohli is a distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.

http://www.tejkohli.com

END

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
kohliventures@buchanan.uk.com
+44 207 466 5000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye